Biogen Inc.

The most important point in this data is the gap between the company's pipeline narrative and the reported numbers available here. Revenue was $9.89 billion in 2025, roughly 31% below the 2019 figure of $14.38 billion. The only operating income figures provided run through 2021, when they were $2.84 billion, down from $4.55 billion in 2020 and $7.04 billion in 2019. Those later profit figures are not in the data, so a reader cannot see from these sources how operating income has moved since 2021. No forensic scores are on file for this company, so this synthesis does not rely on a Beneish M-Score, Piotroski F-Score, Altman Z-Score or Fog Index, and no score-based screen is included here. On the filing text, the company describes a set of launch-stage and collaboration assets, including LEQEMBI with Eisai, SKYCLARYS, the GAZYVA lupus nephritis approval, and the Alcyone acquisition. Alcyone carried total consideration of $85.0 million, with up to $75.0 million more in possible milestones tied to ThecaFlex DRx approval. The Dayra research collaboration on oral macrocyclic peptides is early-stage by its nature. The filings also reference a $5.0 billion share repurchase program authorized under the 2020 Share Repurchase Program, but the data does not show how much of that authorization has been used. The Item 4 conclusion is that disclosure controls were effective as of March 31, 2026, with no changes in internal control during the quarter. Readers may want to look at the Note 20 litigation disclosure and the revenue discussion in the full MD&A to understand what is driving the 2025 change.

Catalyst.Per the data provided, Biogen's 2025 revenue was $9.89 billion, up from $9.68 billion in 2024, a rise of about 2.2%, after declining from $14.38 billion in 2019. The filings point to newer products as the growth focus: LEQEMBI, the Alzheimer's treatment commercialized with Eisai, is in the early stages of launch in the U.S. and certain international markets, and SKYCLARYS is in early launch in certain European markets. GAZYVA received approval for lupus nephritis in October 2025. The company also completed the November 2025 acquisition of Alcyone Therapeutics to develop ThecaFlex DRx, a delivery device for SPINRAZA. The MD&A excerpt provided does not include a revenue discussion, so the drivers of the 2025 change are not explained in this data.

Hidden risk.The risk-factor text says Biogen is substantially dependent on revenue from its products and its anti-CD20 programs, and that competition from generics, biosimilars and new originator therapies, plus pricing pressure including possible drug price negotiation under the IRA, could reduce revenue. The company also markets its own biosimilars (BENEPALI, IMRALDI and FLIXABI), so it operates on both sides of that competition. Launch-stage products add uncertainty that depends partly on Eisai's reimbursement and commercial execution for LEQEMBI. Currency is another exposure: a hypothetical 10% adverse move would reduce the fair value of forward contracts by about $254.1 million at March 31, 2026, compared with $278.0 million at December 31, 2025. The legal proceedings section incorporates Note 20 by reference, and that note is not included in this data.